BioNTech sees up to 17 billion eur in vaccine revenue this year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pfizer (PFE) Asks FDA to Amend EUA and Include Booster for Everyone 18+, Analyst Sees Good Chances for Winning Approval and Upgrades BioNTech (BNTX) to Buy
November 11, 2021 9:01 AM ESTYesterday, Germany recommended only the Covid-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech (NYSE: BNTX) for under the 30s as it causes fewer heart inflammations in younger people than the Moderna (NASDAQ: MRNA).
The committee also recommended pregnant women receive only the BioNTech/Pfizer vaccine.
In the meantime, two... More
BioNTech (BNTX) PT Lowered to $289 at Goldman Sachs
November 11, 2021 7:19 AM ESTGoldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $289.00 (from $433.00) while maintaining a Neutral rating.
The analyst commented, "While vaccine marketplace trends continue to provide tailwinds for mRNA-vaccine manufacturers, more hesitant management commentary around the endemic phase... More
